Macro-economic calculation of spending versus micro-economic follow-up of costs of breast cancer;Reconstitution macro-économique des dépenses, suivi micro-économique des coûts du cancer du sein

Revue d'Epidemiologie et de Sante Publique

Volumn 50, Issue 6, 2002, Pages 581-592

  Borella, L ^a   Paraponaris, A ^a  

^a NONE

Author keywords

breast cancer; Diagnosis related Group; Economics; Hospital cost; Methods

Indexed keywords

ACCURACY; ARTICLE; BREAST CANCER; CALCULATION; CANCER INCIDENCE; COST OF ILLNESS; DATA BASE; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; FOLLOW UP; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; RELIABILITY; THEORETICAL MODEL;

EID: 0346768354     PISSN: 03987620     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Brooten D. Methodological issues linking costs and outcomes. Med Care 1997; 35: NS87-95.
2. Chang WY, Henry BM. Methodologic principles of cost analyses in the nursing, medical, and health services literature, 1990-1996. Nurs Res 1999; 48: 94-104.
3. El M'Rini T, Arveux P, Gay C, Woronoff-Lemsi MC, Gautier C, Gaillard et al. Estimation of the treatment cost of cervical cancer. Rev Epidemiol Sante Publique 1997; 45: 508-15.
4. Bonnema J, van Wersch AM, Van Geel AN, Pruyn JF, Schmitz PI, Uyl D et al. Cost of care in a randomised trial of early hospital discharge after surgery for breast cancer. Eur J Cancer 1998; 34: 2015-20.
5. Brown RE, Hutton J. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anti-Cancer Drugs 1998; 9: 899-907.
6. Hogan AJ. Methodological issues in linking costs and health outcomes in research on differing care delivery systems. Med Care 1997; 35: NS96-105.
7. Bried EM, Scheffier RM. The financial stages of cancer in the elderly. Oncology 1992; 6: 153-60.
8. Etzioni R, Urban N, Baker M. Estimating the costs attributable to a disease with application to ovarian cancer. J Clin Epidem 1996; 49: 95-103.
9. Lave JR, Pashos CL, Anderson GF, Brailer D, Bubolz T, Conrad D et al. Costing medical care: using Medicare administrative data. Med Care 1994; 32: JS77-89.
10. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995; 33: 828-41.
11. Lipscomb J, Ancukiewicz M, Parmigiani G, Hasselblad V, Samsa G, Matchar DB. Predicting the cost of illness: a comparison of alternative models applied to stroke. Med Decision Making 1998; 18: S39-56.
12. Hillner BE, McDonald MK, Desch CE, Smith TJ, Penberthy LT, Maddox P et al. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort. J Clin Oncol 1998; 16: 1420-4.
13. Barnett PG. Review of methods to determine VA health care costs. Med Care 1999; 37: AS9-17.
14. Fireman BH, Quesenberry CP, Somkin CP, Jacobson AS, Baer D, West D et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev 1997; 18: 51-76.
15. Schraub S, Arveux P, Mercier M, Gauthier M. Surgical health care patterns and cancer cost: two studies using population registry data. Rev Epidemiol Sante Publique 1996; 44 (Suppl 1): S33-9.
16. Evans WK, Will BP, Berthelot JM, Wolfson MC. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Can J Oncol 1995; 5: 408-19.
17. Tsao H, Rogers GS, Sober AJ. An estimate of the annual direct cost of treating cutaneous melanoma. J A Acad Dermatol 1998; 38: 669-80.
18. Warner DC, McCandless RR, De Nino LA, Cornell JE, Pugh JA, Marsh GM. Costs of diabetes in Texas, 1992. Diabetes Care 1996; 19: 1416-9.
19. Bonneux L, Barendregt JJ, Nusselder WJ, Der MP. Preventing fatal diseases increases healthcare costs: cause elimination life table approach. Br Med J 1998; 316: 26-9.
20. Chapko MK, Hedrick S. Cost as a study outcome: sensitivity of study conclusions to the method of estimating cost. Med Care 1999; 37: AS37-44.
21. Jonsson B. Diabetes: the cost of illness and the cost of control. An estimate for Sweden 1978. Acta Med Scand Suppl 1983; 671: 19-27.
22. Thom TJ. Economic costs of neoplasms, arteriosclerosis, and diabetes in the United States. In Vivo 1996; 10: 255-9.
23. Borella L, Peuvrel P, Sauvage M, Maraninchi D, Philip T. Un essai d'exploitation de la base PMSI nationale pour évaluer le volume et les modes de prise en charge du cancer, en secteur hospitalier non lucratif. Rev Epidemiol Sante Publique 2000; 48: 53-70.
24. Richards MA, Braysher S, Gregory WM, Rubens RD, Advanced breast cancer: use of ressources and cost implications. Br J Cancer 1993; 67: 856-60.
25. Perkel SJ. Financial modeling for global pricing: the NCCN breast cancer prototype. National Comprehensive Cancer Network. Oncology 1999; 13: 73-4.
26. Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer traitment: rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993; 85: 1460-74.
27. Hillner BE. Economic and cost-effectiveneness issues in breast cancer treatment, Semin Oncol 1996; 23: 98-104.
28. Legoretta AP, Brooks RJ, Leibowitz AN, Solin LJ. Cost of breast cancer treatment. A 4 years longitudunal study. Arch Intern Med 1996; 156: 2197-201.
29. Hurley SF, Huggins RM, Snyder RD, Bishop JF. The cost of breast cancer recurrences. Br J Cancer 1992; 65: 449-55.
30. Will BP, Le Petit C, Berthelot JM, Tomiak EM, Verma S, Evans WK. Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs. Br J Cancer 1999; 79: 1428-36.
31. Lapeyre-Mestre M, Daly-Schveitzer N, Boussin G, Delande G. Evaluation coût-efficacité de la prise en charge du cancer du sein. Analyse comparative 1975-1985 dans un Centre de Lutte Contre le Cancer. Rev Epidemiol Sante Publique 1993; 41: 397-406.
32. o 96/7bis.
33. Ministère de l'Emploi et de la Solidarité. Bilan de l'exécution du PMSI- Synthèse 1995 et données détaillées 1996-1997.
34. Ménégoz F, Black RJ, Arveux P et al. Cancer Incidence and mortality in France in 1975-1995. Eur J Cancer Prev 1997; 6: 442-66.
35. Ménégoz F et al. Le cancer en France: incidence et mortalité. Situation en France en 1995, évolution entre 1975 et 1995. Paris: La Documentation Française, 1998.
36. Fédération Nationale des Centres de Lutte Contre le Cancer. Standards, options et recommandations. Cancers du sein non-métastatiques. Paris: Arnette-Blackwell, 1996.
37. Réseau Convergence Cancer (R2C), Cancers gynécologiques. Cancers du sein. Options thérapeutiques 1996: 57 p.
38. Butler JRG, Furnival CM, Hart RFG. Estimating treatment cost functions for progressive diseases: a multiproduct approach with an application to breast cancer. J Health Economics 1995; 14: 361-85.
39. Lezzoni LI, Henderson MG, Bergman A, Drews RE. Purpose of admission and resource use during cancer hospitalizations. Health Care Financ Rev 1991; 13: 29-40.
40. Quantin C, Entezam F, Bourdais C et al. Modélisation de la distribution des durées de séjour et des coûts dans deux groupes homogènes de malades, d'hématologie et de pneumologie: caractérisation clinique des patients de longue durée et de coût élevé. Rev Epidemiol Sante Publique 1997; 45: 117-30.
41. Baker MS, Kessler LG, Urban N, Smucker RC. Estimating the treatment costs of breast and lung cancer. Med Care 1991; 29: 40-9.
42. Hodgson TA, Meiners M. Cost of illness methodology: a guide to current procedures. Millbank Memor Fund Quart 1982; 60: 429-62.